Back to Research Home
MRKMerck & Company Inc
Health Care · Pharmaceuticals · Mega
$145.27−1.34%
As of 23 Oct 2026Mkt cap $374B
Stage 13
AVOID
Fundamentals
37.2/75
Technical
5.7/15
Independent
42.9/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- −1.8%
- 3M
- +11.1%
- 6M
- +29.8%
- 1Y
- +65.8%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 116.2xHist median 15.3x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 22.7x
- FCF yield
- 4.4%
Quality
- ROIC
- 24.0%
- Operating margin
- 31.5%
- FCF margin
- 19.0%
- Current ratio
- 1.5x
Growth
- Revenue growth
- +1.3%Latest FY YoY
- Revenue CAGR
- +7.5%
- EPS CAGR
- +9.1%
- FCF CAGR
- +9.3%
Capital
- Share-count trend
- −0.8%3Y annualised
- Net debt
- $36.0B2.2x OCF
Annual trend
- CAGR 2021–2025
- +7.5%
- Latest · 2025
- $65B
- YoY
- +1.3%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-29
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded